Tandem Diabetes Care (TNDM) Change in Receivables (2013 - 2026)

Tandem Diabetes Care's Change in Receivables history runs 14 years deep, the most recent figure standing at -$22.7 million for Q1 2026.

• Quarterly Change in Receivables fell 309.17% year-over-year to -$22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (down 43.75% YoY) and the FY2025 annual result came in at $56.8 million, up 173.2% from the prior year.
• Change in Receivables was -$22.7 million for Q1 2026 at Tandem Diabetes Care, down from $42.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $42.0 million in Q4 2025 and bottomed at -$22.8 million in Q1 2023.
• A 5-year average of $3.4 million and a median of $5.6 million in 2023 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2025 — Change in Receivables soared 247.71% — and 2026, when it tumbled 309.17%.
• Tandem Diabetes Care's Change in Receivables stood at $3.0 million in 2022, then jumped by 84.41% to $5.6 million in 2023, then surged by 115.96% to $12.1 million in 2024, then surged by 247.71% to $42.0 million in 2025, then plunged by 153.98% to -$22.7 million in 2026.
• Business Quant data shows TNDM's Change in Receivables at -$22.7 million in Q1 2026, $42.0 million in Q4 2025, and $1.3 million in Q3 2025.